HepaRegeniX: FDA Grants Orphan Drug Status to Darizmetinib
Tuebingen, Germany — August 26, 2026 HepaRegeniX GmbH announced that the U.S. FDA has granted Orphan Drug Designation (ODD)...
MolDX
Advertisement
IMUNON Highlights Phase 3 OVATION 3 Trial at R&D Day
Lawrenceville, New Jersey – August 26, 2026 IMUNON announced plans to host its 2026 R&D Day on September 23...
NeoGenomics Gains Medicare Coverage for RaDaR ST Monitoring
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
Insight Molecular Diagnostics Advances GraftAssureDx FDA Review
NASHVILLE, Tennessee, August 10, 2026 Insight Molecular Diagnostics, Inc. (iMDx) reported second-quarter 2026 results and provided an update on...
Natera Validates Tissue-Free MRD Test in Colorectal Cancer
Austin, Texas, January 21, 2026 — Natera, a global leader in cell-free DNA and precision medicine, announced the peer-reviewed...
Advertisement
